Table 3. Cost‐effectiveness in the base‐case analyses.
First‐generation tyrosine kinase inhibitors compared with SOC (the reference strategy) for advanced non‐small cell lung cancer harboring epidermal growth factor receptor mutation.
Abbreviations: CNS, central nervous system; LY, life year; QALY, quality‐adjusted life year; SOC, standard of care.